

DIMERIX INVESTOR WEBINAR**Investor Webinar | Tuesday, 16 June 2026 – 11.30am AEST**

You are invited to register using this link:

https://us02web.zoom.us/webinar/register/WN_VPdCCoPETuq8dvsUso1vnm

Participants may submit questions at registration or during the session

MELBOURNE, Australia, 16 June 2026: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease – DMX-200 – is pleased to provide an opportunity for shareholders, investors and brokers to join a live streamed presentation where Dimerix CEO & Managing Director, Dr Nina Webster, will discuss today's announcement on the licensing transaction with Everest Medicines for DMX-200 in Greater China, South Korea and Southeast Asia, as well as the Phase 3 clinical trial progress.

The presentation is attached to this announcement.

Authorised for lodgement with ASX by the Board of Dimerix.

—END—

About ACTION3 Phase 3 Study

The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo.

The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval. Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

About DMX-200

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan¹.

About FSGS

FSGS is a serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. The pathogenesis of FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In China, 500,000 to 1 million people are estimated to be living with FSGS,² including both adults and children. Management relies on non-specific immunosuppressive and supportive therapies in most countries around the world. In patients with progressive or treatment-resistant FSGS, the time from diagnosis to end-stage kidney disease can be as short as five years. Even among those with FSGS who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,³ underscoring the urgent need for new disease-modifying treatments.

About Dimerix Limited

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company's website at www.dimerix.com and follow on [X](#) and [LinkedIn](#).

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website at www.everestmedicines.com.

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially

from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

DIMERIX CONTACTS

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Jane Lowe
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

References

- 1 ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025
- 2 Yang Y, Zhang Z, Zhuo L, Chen DP, Li WG. (2018) The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. *Chin Med J (Engl)*, 131(6):731–735; and Du X, Xiao D, Ao C, Zhang Y, Xuan J. Disease Burden of IgA Nephropathy in China. ISPOR Europe 2021. (poster/presentation)
- 3 *Front. Immunol.*, (July 2019) | <https://doi.org/10.3389/fimmu.2019.01669>



Dimerix

ACTION3
FSGS CLINICAL STUDY

Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs

Licensing Webinar - China

16 June 2026



Authorised for lodgement by the Board of the Company

ersonal use only

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties.

Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

Phase 3 Global Opportunity

5 commercial partners

DMX-200 licensed
USA, EU, Canada, Australia, NZ, Japan, China, S.Korea, SEA and GCC¹

up to \$1.9 billion

in total development and sales milestone payments **plus** royalties on net sales¹

Phase 3 trial

recruitment complete in trial of DMX-200 in focal segmental glomerulosclerosis (FSGS)²

FSGS indication

is a **rare disease** that causes scarring of the kidney, leading to irreversible damage³

Reduced risk

- ▶ Proteinuria endpoint **passed blinded interim** (futility) assessment¹
- ▶ Blinded review confirmed ACTION3 **statistically powered (>90%)** to demonstrate statistical significance of predicted proteinuria treatment effect of DMX-200⁴

Orphan drug designations

regulatory, marketing exclusivity and pricing **benefits** in key territories⁵

~\$1.9 billion*

5 commercial licensing partners

*total upfront and potential milestone payments + royalties on net sales


1. Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026; SEA = Southeast Asia, GCC = Gulf Cooperation Council; 2. AS release 10 March 2026; 3. ASX release 28 April 2026; 3. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: <https://www.ncbi.nlm.nih.gov/books/NBK532272/>; 4. ASX release 11 March 2024 and 28 April 2026; 5. ASX releases: 14 December 2015, 21 November 2018, 07 June 2021 and 30 September 2025

Cycle of damage in glomerular diseases

What is FSGS?

Focal = some
Segmental = sections
Glomerulo = of the kidney filtering units
Sclerosis = are scarred

Existing blood pressure medication



1. Lewis, E. J. et al. (2001), *New Engl J Medicine* 345, 851-860

Everest Medicines: a fully integrated commercialisation platform

Better Medicines, Better Life

¥2.7 billion RMB
Cash Balance
end 2025

Substantial revenue
growth
¥1.71 billion RMB
in 2025



First Medicine in
China for IgA
Nephropathy

Leverageable
Kidney Disease
Infrastructure



ersonal use only

Everest–Dimerix partnership: well-aligned towards driving success

Everest Medicines delivers specialised therapies for high unmet needs across Greater China and the Southeast Asian region

Focusing on Differentiated Therapeutic Areas and Building a Leading Commercialization Platform

- Everest has established a lean and efficient commercialisation platform, driving the successful launch and commercial profitability of multiple products

Everest expertise in gaining approval and launching rare kidney disease medicines in the territories

- Everest brings strong experience and expertise in the regulatory submission, with proven success in the launch of NEFECON® in IgA nephropathy, a rare type of kidney disease

Market access expertise

- Proven capability navigating China's National Reimbursement Drug List (NRDL) reimbursement, pricing, and hospital access in kidney disease, through existing call-points to bring DMX-200 to the Greater China, South Korean and Southeast Asian markets

Partnership for growth


- Significantly expands the potential reach of DMX-200 into a large and underserved patient population, providing real hope for patients with FSGS across the globe in need of treatment options




Key elements of **EVEREST MEDICINES** partnership

Personal use only


Dimerix to receive:
**up to US\$340 million
(~AU\$481 million*)**
in upfront and potential development and sales milestone payments, plus royalties




Everest acquires exclusive license to commercialise DMX-200 for all indications in Greater China, South Korea and Southeast Asia




Everest will be responsible for preparation, submission and maintenance of the regulatory dossier in the licensed territories, as well as all sales and costs of marketing activities



- US\$10 million (~AU\$14.1 million*) within 45 days of execution
- up to US\$330 million (~AU\$467 million*) in potential development and sales milestones
- Tiered royalties on net sales 10-15%




Dimerix will continue to fund and execute the global ACTION3 Phase 3 study for DMX-200 in FSGS patients



Dimerix retains all rights to DMX-200 in all other unlicensed territories

Global strategic partnering expansion



Everest licensed territories¹
500,000-1 million people are estimated to be living with FSGS

New drug exclusivity framework in China effective May 15, 2026;
5-7 years exclusivity + 2 years for paediatric indication²

Dimerix continues to pursue and progress licensing opportunities with potential partners outside the licensed territories

Personal use only

Yang Y, Zhang Z, Zhuo L, Chen DP, Li WG. (2018) The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. Chin Med J (Engl), 131(6):731-735; and Du X, Xiao D, Ao C, Zhang Y, Xuan J. (2021) Disease Burden of IgA Nephropathy in China. ISPOR Europe (poster/presentation); 2. Wang, S, (2026) China | Market Exclusivity and Data Exclusivity included in Drug Administration Law <https://www.spruson.com/china-market-exclusivity-data-exclusivity-in-drug-administration-law-revisions>

Summary of licensing deals for DMX-200 to date

Dimerix has successfully partnered DMX-200 across multiple key markets


Licensing deals collectively valued up to

~AU\$1.9 billion

in total upfront and potential milestone fees plus royalties

>AU\$80 million

in total payments received



1. Based on US conversions & further terms outlined in ASX Announcement on 16 June 2026; 2. Based on US conversions & further terms outlined in ASX Announcement on 01 May 2025; 3. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023; 4. Based on US dollar conversions & further terms outlined in ASX Announcement on 27 May 2024; 5. Based on Japanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025

ACTION3 phase 3 clinical trial

FSGS CLINICAL STUDY



A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286)

Background

- Patients recruited, then screened and stabilised on background medications
- Patients randomised to receive drug or placebo
- DXB remains blinded at all times during study

Phase 3 Trial Timeline

Successful interim analysis¹
(using statistical measure)
72 patients @ 35 weeks
(% change in uPCR)

Planned blinded
statistical powering
review²

Final analysis:
Primary = uPCR
Secondary = eGFR²
@104 weeks

ARB + placebo



ARB + DMX-200

demonstrated DMX-200 was performing better than placebo at that point in time¹

ACTION3 remains appropriately statistically powered (>90%) to demonstrate a treatment effect for proteinuria primary endpoint²

ACTION3 Study End

Open Label Extension


DMX-200
75/81 (93%)³ patients enrolled in open label extension study to date

1. ASX release 11 March 2024, Predictive Power statistical model using industry standard as set by the independent renal biostatistician consultant for Dimerix, blinded interim Phase 3 analysis data does not guarantee a statistically significant outcome at the end of the trial; 2. ASX release 28 April 2026; 3. number and % of eligible patients who have completed 2 years treatment and elected to enter the OLE as at 16 June 2026; ARB = angiotensin receptor blocker; uPCR = urinary proteinuria; eGFR = estimated glomerular filtration rate (kidney function);

Adult patient recruitment by territory



Trial designed for potential approval globally



Recruitment completed
(adult population)¹



333
Adult patients recruited, randomised and dosed (target ≥286)²










Personal use only

1. ASX release 15 December 2025; 2. Final numbers of adult patients, ASX release 10 March 2026; paediatric patients will continue to recruit, and will not impact final analysis timelines

DMX-200 substantially reduced risk Phase 3 renal asset



<p>Blinded interim (futility) assessment: drug performing better than placebo at reducing proteinuria (March 2024)¹</p> <p>Efficacy signal</p> 	<p>>90% statistical power for ACTION3 primary endpoint: proteinuria to resolve DMX-200 treatment effect (April 2026)²</p> <p>Statistical powering</p> 	<p>Passed 8 safety data monitoring meetings with no protocol changes requested, most recently in June 2026</p> <p>Safety profile</p> 	<p>Study fully recruited: fixed timelines to full study completion in Q1 2028³</p> <p>Fully recruited</p> 
<p>Strong uptake into open label extension study: indicates patient willingness to continue treatment</p> <p>Open label extension</p> 	<p>~\$1.9 billion in upfront/potential milestones + royalties with 5 commercial partners across key territories⁴</p> <p>Commercial validation</p> 	<p>Indication extension: DMX-200 proposed mechanism of action potentially suited to other inflammatory renal indications</p> <p>Additional indications</p> 	

1. ASX release ASX release 11 March 2024 ; 2. ASX release 28 April 2026; 3. ASX release 10 March 2026; 4. Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026;

Personal use only

Corporate overview

Ticker Symbol	ASX: DXB
Cash Balance (Mar26)*	\$26.6 million
Market Capitalisation ¹	\$102 million
Share price ¹	\$0.17
Total ordinary shares on issue ¹	600,396,776
Average Daily Liquidity by value for past 30 trading days ²	\$0.62 million

Research Coverage	Analyst
EUROZ HARTLEYS	Seth Lizee
PETRA CAPITAL	Tanushree Jain

*excluding Everest upfront payment of ~AU\$14 million†



SUBSTANTIAL SHAREHOLDERS³

Position	Holder Name	Holding	% IC
1	Mr P Meurs	87,259,311	14.5%
TOTAL (TOP 5) Shareholders		146,084,078	24.3%

†Based on XE rate of 1 USD = 1.41612 AUD as at 15 June 2026; 1. As at 15 June 2026; 2. Past 30 trading days liquidity as at 15 June 2026; 3. Shareholder register as at 15 June 2026

Growth strategy



Deliver ACTION3 Phase 3 clinical trial

- Ensure drug supply continuity and patient visits for recruited patients
- Complete recruitment of paediatric patients
- Maintain regulatory engagement (FDA, EMA, PMDA, NMPA + others)
- With partners, prepare for potential market approval and launch readiness



Expand global commercial partnerships

- Build on existing licensing agreements and relationships
- Secure additional partnerships to expand and accelerate market access



Advance pipeline development

- Identify and progress new assets in renal and/or rare disease indications
- Leverage DMX-200 platform for additional indications

Grow sustainable shareholder value through clinical success, global partnerships, and pipeline diversification



Dimerix

(ASX:DXB)



WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

Dimerix HQ

425 Smith St, Fitzroy 3065
Victoria, Australia
T. +61 1300 813 321
E. investor@dimerix.com